MCID: 8P1002
MIFTS: 39

8p11 Myeloproliferative Syndrome

Categories: Blood diseases, Cancer diseases, Immune diseases, Liver diseases, Rare diseases

Aliases & Classifications for 8p11 Myeloproliferative Syndrome

MalaCards integrated aliases for 8p11 Myeloproliferative Syndrome:

Name: 8p11 Myeloproliferative Syndrome 25
Myeloid and Lymphoid Neoplasms with Fgfr1 Abnormalities 25
Myeloid and Lymphoid Neoplasms with Fgfr1 Rearrangement 71
Chromosome 8p11 Myeloproliferative Syndrome 71
8p11 Stem Cell Leukemia/lymphoma Syndrome 25
Stem Cell Leukemia/lymphoma 25
8p11 Stem Cell Syndrome 25

Classifications:



External Ids:

UMLS 71 C2827362 C3150773

Summaries for 8p11 Myeloproliferative Syndrome

Genetics Home Reference : 25 8p11 myeloproliferative syndrome is a blood cancer that involves different types of blood cells. Blood cells are divided into several groups (lineages) based on the type of early cell from which they are descended. Two of these lineages are myeloid cells and lymphoid cells. Individuals with 8p11 myeloproliferative syndrome can develop both myeloid cell cancer and lymphoid cell cancer. The condition can occur at any age. It usually begins as a myeloproliferative disorder, which is characterized by a high number of white blood cells (leukocytes). Most affected individuals also have an excess of myeloid cells known as eosinophils (eosinophilia). In addition to a myeloproliferative disorder, many people with 8p11 myeloproliferative syndrome develop lymphoma, which is a form of blood cancer that involves lymphoid cells. The cancerous lymphoid cells grow and divide in lymph nodes, forming a tumor that enlarges the lymph nodes. In most cases of 8p11 myeloproliferative syndrome, the cancerous cells are lymphoid cells called T cells. Lymphoma can develop at the same time as the myeloproliferative disorder or later. In most people with 8p11 myeloproliferative syndrome, the myeloproliferative disorder develops into a fast-growing blood cancer called acute myeloid leukemia. The rapid myeloid and lymphoid cell production caused by these cancers results in enlargement of the spleen and liver (splenomegaly and hepatomegaly, respectively). Most people with 8p11 myeloproliferative syndrome have symptoms such as fatigue or night sweats. Some affected individuals have no symptoms, and the condition is discovered through routine blood tests.

MalaCards based summary : 8p11 Myeloproliferative Syndrome, also known as myeloid and lymphoid neoplasms with fgfr1 abnormalities, is related to chromosome 8p11 myeloproliferative syndrome and lymphoblastic lymphoma. An important gene associated with 8p11 Myeloproliferative Syndrome is FGFR1 (Fibroblast Growth Factor Receptor 1), and among its related pathways/superpathways are HIV Life Cycle and Cytokine Signaling in Immune system. The drugs Mesna and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include myeloid, lymph node and t cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for 8p11 Myeloproliferative Syndrome

Diseases in the 8p11 Myeloproliferative Syndrome family:

Myeloproliferative Syndrome, Transient Myeloproliferative Disease, Autosomal Recessive

Diseases related to 8p11 Myeloproliferative Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Related Disease Score Top Affiliating Genes
1 chromosome 8p11 myeloproliferative syndrome 34.9 SCLL RANBP2 FGFR1
2 lymphoblastic lymphoma 31.2 ZMYM2 FGFR1OP2 FGFR1
3 hypereosinophilic syndrome 30.9 PDGFRB KIT FGFR1
4 acute leukemia 30.0 RUNX1 KIT FLT3 BCR
5 myelodysplastic/myeloproliferative neoplasm 30.0 PDGFRB KIT FLT3
6 atypical chronic myeloid leukemia 29.5 RUNX1 PDGFRB FLT3 FGFR1
7 leukemia, chronic myeloid 29.2 RUNX1 PDGFRB KIT FLT3 FGFR1 BCR
8 leukemia, acute myeloid 29.0 RUNX1 PDGFRB KIT KDR FLT3 FGFR1
9 chronic myelomonocytic leukemia 28.9 RUNX1 PDGFRB KIT KDR FLT3
10 hematologic cancer 28.7 RUNX1 PDGFRB KIT KDR FLT3 FGFR1
11 myelodysplastic syndrome 28.6 RUNX1 PDGFRB KIT KDR FLT3
12 myeloproliferative neoplasm 28.4 ZMYM2 RUNX1 PDGFRB MYO18A KIT KDR
13 myeloid leukemia 10.4
14 polykaryocytosis inducer 10.3
15 rare tumor 10.3
16 leukemia 10.2
17 lymphoma, hodgkin, classic 10.2
18 lymphoma, non-hodgkin, familial 10.2
19 leukemia, acute lymphoblastic 10.2
20 peripheral t-cell lymphoma 10.2
21 thrombocytopenia 10.2
22 t-cell lymphoblastic leukemia/lymphoma 10.2
23 monocytic leukemia 10.2
24 myeloid sarcoma 10.2
25 primary hypereosinophilic syndrome 10.2 PDGFRB FGFR1
26 acute myeloblastic leukemia with maturation 10.1 KIT FLT3
27 b-lymphoblastic leukemia/lymphoma 10.1 ZMYM2 KIT FGFR1
28 lymphoma 10.1
29 pulmonary vein stenosis 10.1 KIT KDR
30 myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1 10.1 ZMYM2 PDGFRB FGFR1
31 achondroplasia, severe, with developmental delay and acanthosis nigricans 10.0 FGFR1 FGF1
32 myeloid and lymphoid neoplasms associated with fgfr1 abnormalities 10.0 ZMYM2 FLT3 FGFR1OP2 FGFR1
33 systemic mastocytosis 9.9 PDGFRB KIT FGFR1
34 precursor t-cell acute lymphoblastic leukemia 9.9
35 myeloid and lymphoid neoplasms associated with pdgfra rearrangement 9.9 PDGFRB KIT FGFR1
36 hypereosinophilic syndrome, idiopathic 9.9 PDGFRB KIT
37 sarcomatous intrahepatic cholangiocarcinoma 9.9 PDGFRB KIT
38 mesenchymal cell neoplasm 9.9 RANBP2 PDGFRB KIT
39 leukemia, acute lymphoblastic 3 9.8 RUNX1 FLT3 BCR
40 acute myeloid leukemia with t(8;21)(q22;q22) translocation 9.8 RUNX1 KIT FLT3
41 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 9.8 RUNX1 KIT FLT3
42 core binding factor acute myeloid leukemia 9.8 RUNX1 KIT FLT3
43 cebpa-associated familial acute myeloid leukemia 9.8 RUNX1 KIT FLT3
44 vascular cancer 9.7 PDGFRB KIT KDR
45 fibrosarcoma of bone 9.7 KIT KDR
46 mastocytosis 9.7 PDGFRB KIT FLT3 FGFR1
47 gliosarcoma 9.7 PDGFRB KDR FGFR1
48 chronic leukemia 9.7 PDGFRB KIT FLT3 BCR
49 blood platelet disease 9.6 RUNX1 KIT FLT3
50 chronic eosinophilic leukemia 9.6 ZMYM2 PDGFRB KIT FLT3 FGFR1

Graphical network of the top 20 diseases related to 8p11 Myeloproliferative Syndrome:



Diseases related to 8p11 Myeloproliferative Syndrome

Symptoms & Phenotypes for 8p11 Myeloproliferative Syndrome

GenomeRNAi Phenotypes related to 8p11 Myeloproliferative Syndrome according to GeneCards Suite gene sharing:

26 (show top 50) (show all 56)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-104 10.06 TPR MYO18A
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.06 TPR
3 Increased shRNA abundance (Z-score > 2) GR00366-A-107 10.06 RANBP2
4 Increased shRNA abundance (Z-score > 2) GR00366-A-109 10.06 RANBP2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-112 10.06 TRIM24
6 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.06 BCR
7 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.06 TPR
8 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.06 TPR
9 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10.06 TRIM24
10 Increased shRNA abundance (Z-score > 2) GR00366-A-139 10.06 TPR
11 Increased shRNA abundance (Z-score > 2) GR00366-A-142 10.06 TRIM24
12 Increased shRNA abundance (Z-score > 2) GR00366-A-145 10.06 CNTRL
13 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.06 KIT
14 Increased shRNA abundance (Z-score > 2) GR00366-A-153 10.06 CNTRL
15 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.06 KIT
16 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.06 BCR
17 Increased shRNA abundance (Z-score > 2) GR00366-A-170 10.06 KIT
18 Increased shRNA abundance (Z-score > 2) GR00366-A-173 10.06 TRIM24
19 Increased shRNA abundance (Z-score > 2) GR00366-A-174 10.06 RANBP2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.06 RANBP2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-205 10.06 TPR
22 Increased shRNA abundance (Z-score > 2) GR00366-A-206 10.06 MYO18A
23 Increased shRNA abundance (Z-score > 2) GR00366-A-215 10.06 BCR
24 Increased shRNA abundance (Z-score > 2) GR00366-A-26 10.06 RANBP2
25 Increased shRNA abundance (Z-score > 2) GR00366-A-27 10.06 MYO18A
26 Increased shRNA abundance (Z-score > 2) GR00366-A-28 10.06 MYO18A
27 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.06 BCR
28 Increased shRNA abundance (Z-score > 2) GR00366-A-3 10.06 MYO18A
29 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.06 KIT
30 Increased shRNA abundance (Z-score > 2) GR00366-A-38 10.06 MYO18A
31 Increased shRNA abundance (Z-score > 2) GR00366-A-53 10.06 KDR
32 Increased shRNA abundance (Z-score > 2) GR00366-A-55 10.06 TRIM24
33 Increased shRNA abundance (Z-score > 2) GR00366-A-56 10.06 CNTRL
34 Increased shRNA abundance (Z-score > 2) GR00366-A-59 10.06 CNTRL RANBP2
35 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.06 KDR TPR TRIM24
36 Increased shRNA abundance (Z-score > 2) GR00366-A-61 10.06 KIT
37 Increased shRNA abundance (Z-score > 2) GR00366-A-65 10.06 MYO18A
38 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.06 CNTRL
39 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.06 BCR KDR KIT TPR TRIM24
40 Increased shRNA abundance (Z-score > 2) GR00366-A-89 10.06 MYO18A RANBP2
41 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.06 KIT
42 Increased shRNA abundance (Z-score > 2) GR00366-A-91 10.06 BCR
43 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.06 KIT
44 Decreased viability GR00173-A 9.89 FLT3
45 Decreased viability GR00221-A-1 9.89 FGFR1 FLT3 KDR KIT PDGFRB
46 Decreased viability GR00221-A-2 9.89 FGFR1 KDR
47 Decreased viability GR00221-A-3 9.89 KDR PDGFRB
48 Decreased viability GR00221-A-4 9.89 FLT3 KDR PDGFRB
49 Decreased viability GR00249-S 9.89 KDR
50 Decreased viability GR00301-A 9.89 KIT

Drugs & Therapeutics for 8p11 Myeloproliferative Syndrome

Drugs for 8p11 Myeloproliferative Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 23)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mesna Approved, Investigational Phase 2 3375-50-6 598
2
leucovorin Approved Phase 2 58-05-9 6006 143
3
Methotrexate Approved Phase 2 59-05-2, 1959-05-2 126941
4
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492 6473866
5
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
6
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
7
Lenograstim Approved, Investigational Phase 2 135968-09-1
8
Clofarabine Approved, Investigational Phase 2 123318-82-1 119182
9
Busulfan Approved, Investigational Phase 2 55-98-1 2478
10
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
11 Folic Acid Antagonists Phase 2
12 Immunosuppressive Agents Phase 2
13 Vitamin B Complex Phase 2
14 Alkylating Agents Phase 2
15 Folate Phase 2
16 Immunologic Factors Phase 2
17 Thymoglobulin Phase 2
18 Calcineurin Inhibitors Phase 2
19 Dermatologic Agents Phase 2
20 Antirheumatic Agents Phase 2
21 Vitamin B9 Phase 2
22 Antimetabolites Phase 2
23 Antilymphocyte Serum Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies Completed NCT00857389 Phase 2 Thiotepa;Clofarabine;Busulfan;Thymoglobulin (ATG);G-CSF (Filgrastim);Tacrolimus;Methotrexate;Cyclophosphamide;Mesna

Search NIH Clinical Center for 8p11 Myeloproliferative Syndrome

Genetic Tests for 8p11 Myeloproliferative Syndrome

Anatomical Context for 8p11 Myeloproliferative Syndrome

MalaCards organs/tissues related to 8p11 Myeloproliferative Syndrome:

40
Myeloid, Lymph Node, T Cells, Spleen, Liver, Testes, B Cells

Publications for 8p11 Myeloproliferative Syndrome

Articles related to 8p11 Myeloproliferative Syndrome:

(show top 50) (show all 104)
# Title Authors PMID Year
1
Oncogenic fusion protein BCR-FGFR1 requires the breakpoint cluster region-mediated oligomerization and chaperonin Hsp90 for activation. 61
31439673 2020
2
8p11 associated myeloid/lymphoid neoplasms: An illustrative case report of this rare entity and review of literature. 61
32296228 2020
3
Functional characterization of two rare BCR-FGFR1+ leukemias. 61
31980503 2020
4
Critical individual roles of the BCR and FGFR1 kinase domains in BCR-FGFR1-driven stem cell leukemia/lymphoma syndrome. 61
31525277 2020
5
The Ems Syndrome (8P11/12 Myeloproliferative Syndrome) or Human Stem Cell Leukemia/Lymphoma Syndrome-A Unique and Rare Case. 61
31979932 2020
6
Rac1/2 activation promotes FGFR1 driven leukemogenesis in stem cell leukemia/lymphoma syndrome. 61
31221776 2020
7
Distinct signaling programs associated with progression of FGFR1 driven leukemia in a mouse model of stem cell leukemia lymphoma syndrome. 61
30439482 2019
8
DNA methyltransferase 1-mediated CpG methylation of the miR-150-5p promoter contributes to fibroblast growth factor receptor 1-driven leukemogenesis. 61
31628193 2019
9
[8p11 myeloproliferative syndrome with t(8;22) (p11; q11): a case report]. 61
31856441 2019
10
[Myeloid/lymphoid neoplasms with eosinophilia and FGFR1 rearrangement: 5 cases report and literatures review]. 61
31775485 2019
11
[8p11 myeloproliferative syndrome with CEP110-FGFR1 fusion in a child]. 61
30934206 2019
12
Allogeneic hematopoietic stem cell transplantation for 8p11 myeloproliferative syndrome with BCR-FGFR1 gene rearrangement: a case report and literature review. 61
30087462 2019
13
Loss of the BCR-FGFR1 GEF Domain Suppresses RHOA Activation and Enhances B-Lymphomagenesis in Mice. 61
30413411 2019
14
[The 8p11 myeloproliferative syndrome: a review of recent literature]. 61
31597839 2019
15
[Clinical and molecular features of one case of 8p11 myeloproliferative syndrome with t(8;17) (p11; q24)]. 61
30612409 2018
16
FGFR1 fusion kinase regulation of MYC expression drives development of stem cell leukemia/lymphoma syndrome. 61
29720732 2018
17
8p11 Myeloproliferative syndrome with t(8;22)(p11;q11): A case report. 61
30116393 2018
18
miR-339 Promotes Development of Stem Cell Leukemia/Lymphoma Syndrome via Downregulation of the BCL2L11 and BAX Proapoptotic Genes. 61
29735550 2018
19
8p11 Stem Cell Leukemia/Lymphoma Syndrome without Myeloproliferation: A Rare Clinical Entity. 61
29622897 2018
20
Precursor T-Lymphoblastic Lymphoma Associated with t(8;9)(p11.2;q33): A Case Report and Review of the Literature. 61
29614500 2018
21
A Case of Myeloproliferative Neoplasm with BCR-FGFR1 Rearrangement: Favorable Outcome after Haploidentical Allogeneic Transplantation. 61
30647980 2018
22
Primary cells in BCR/FGFR1-positive 8p11 myeloproliferative syndrome are sensitive to dovitinib, ponatinib, and dasatinib. 61
28881484 2017
23
Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemia/lymphomas. 61
28646488 2017
24
Myeloproliferative neoplasms with t(8;22)(p11.2;q11.2)/BCR-FGFR1: a meta-analysis of 20 cases shows cytogenetic progression with B-lymphoid blast phase. 61
28551329 2017
25
Activity of fibroblast growth factor receptor inhibitors TKI258, ponatinib and AZD4547 against TPR‑FGFR1 fusion. 61
28138694 2017
26
Diagnostic application of next-generation sequencing in ZMYM2-FGFR1 8p11 myeloproliferative syndrome: A case report. 61
27415155 2016
27
Development of ZMYM2-FGFR1 driven AML in human CD34+ cells in immunocompromised mice. 61
27005999 2016
28
8p11 myeloproliferative syndrome: diagnostic challenges and pitfalls. 61
27569099 2016
29
8p11 Myeloproliferative Syndrome with t(7;8) Translocation Presenting as Acute Myeloid Leukemia: A Case Report and Literature Review. 61
27188774 2016
30
Restored expression of vitamin D receptor and sensitivity to 1,25-dihydroxyvitamin D3 in response to disrupted fusion FOP2-FGFR1 gene in acute myeloid leukemia cells. 61
26839680 2016
31
Functional characterization, localization, and inhibitor sensitivity of the TPR-FGFR1 fusion in 8p11 myeloproliferative syndrome. 61
26391436 2016
32
[8p11 myeloproliferative syndrome with CEP110-FGFR1 fusion in a patient]. 61
26418991 2015
33
8p11 myeloproliferative syndrome: a case report of this rare clinical entity. 61
25885151 2015
34
[Clinical and gene involved of one case of 8p11 myeloproliferative syndrome with ins(13;8)(q12;p11p23)]. 61
25916288 2015
35
Screening of drugs to treat 8p11 myeloproliferative syndrome using patient-derived induced pluripotent stem cells with fusion gene CEP110-FGFR1. 61
25803811 2015
36
8p11 myeloproliferative syndrome with t(1;8)(q25;p11.2): a case report and review of the literature. 61
25227135 2015
37
Molecular identification of a TPR-FGFR1 fusion transcript in an adult with myeloproliferative neoplasm, T-lymphoblastic lymphoma, and a t(1;8)(q25;p11.2). 61
25037443 2014
38
FGF receptors: cancer biology and therapeutics. 61
23696246 2014
39
[8p11 myeloproliferative syndrome cured by allogeneic hematopoietic stem cell transplantation: two case reports and literature review]. 61
24343089 2013
40
Quantitative polymerase chain reaction detection of CEP110-FGFR1 fusion gene in a patient with 8p11 myeloproliferative syndrome. 61
23327291 2013
41
[8p11 myeloproliferative syndrome]. 61
23998615 2013
42
A case of acute myelogenous leukaemia characterised by the BCR-FGFR1 translocation. 61
23519513 2013
43
Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome. 61
22875613 2013
44
A case of 8p11 myeloproliferative syndrome with BCR-FGFR1 gene fusion presenting with trilineage acute leukemia/lymphoma, successfully treated by cord blood transplantation. 61
23171834 2013
45
Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities. 61
22781593 2013
46
Identification of a novel partner gene, TPR, fused to FGFR1 in 8p11 myeloproliferative syndrome. 61
22619110 2012
47
Favorable outcome of allogeneic hematopoietic cell transplantation for 8p11 myeloproliferative syndrome associated with BCR-FGFR1 gene fusion. 61
22106025 2012
48
A novel t(1;8)(q25;p11.2) translocation associated with 8p11 myeloproliferative syndrome. 61
21848523 2012
49
Src activation plays an important key role in lymphomagenesis induced by FGFR1 fusion kinases. 61
21937681 2011
50
Constitutive Notch pathway activation in murine ZMYM2-FGFR1-induced T-cell lymphomas associated with atypical myeloproliferative disease. 61
21527531 2011

Variations for 8p11 Myeloproliferative Syndrome

Expression for 8p11 Myeloproliferative Syndrome

Search GEO for disease gene expression data for 8p11 Myeloproliferative Syndrome.

Pathways for 8p11 Myeloproliferative Syndrome

Pathways related to 8p11 Myeloproliferative Syndrome according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.44 ZMYM2 TRIM24 TPR RANBP2 PDGFRB MYO18A
2
Show member pathways
13.24 TPR RANBP2 PDGFRB KIT FLT3 FGFR1
3
Show member pathways
13.18 PDGFRB KIT KDR FLT3 FGFR1 FGF1
4
Show member pathways
13.14 PDGFRB KIT KDR FLT3 FGFR1 FGF1
5
Show member pathways
12.88 PDGFRB KIT KDR FLT3 FGFR1 FGF1
6
Show member pathways
12.82 PDGFRB KIT KDR FLT3 FGFR1
7
Show member pathways
12.75 TPR RUNX1 PDGFRB KIT FLT3 FGFR1
8 12.67 PDGFRB KIT KDR FLT3 FGFR1 FGF1
9 12.65 TPR RUNX1 PDGFRB KIT FLT3 FGFR1
10
Show member pathways
12.62 PDGFRB KIT KDR FLT3 FGFR1 FGF1
11
Show member pathways
12.37 TRIM24 PDGFRB KDR FGFR1
12
Show member pathways
12.36 KDR FGFR1OP2 FGFR1 CEP43
13
Show member pathways
12.31 PDGFRB KIT KDR FLT3 FGFR1 FGF1
14
Show member pathways
12.17 PDGFRB KIT KDR FGFR1 FGF1
15 11.92 RUNX1 PDGFRB KDR
16 11.87 PDGFRB KIT KDR FLT3 FGFR1 FGF1
17
Show member pathways
11.81 ZMYM2 TRIM24 MYO18A FGFR1OP2 FGFR1 FGF1
18 11.76 PDGFRB KDR FGFR1 FGF1
19
Show member pathways
11.69 PDGFRB KIT KDR FLT3 FGFR1
20 11.62 PDGFRB KIT FLT3 FGFR1
21
Show member pathways
11.47 PDGFRB KIT BCR
22 11.37 PDGFRB KDR FGFR1 FGF1
23
Show member pathways
11.24 PDGFRB KIT KDR FLT3
24
Show member pathways
11.23 ZMYM2 TRIM24 MYO18A FGFR1OP2 FGFR1 FGF1
25 10.93 PDGFRB KIT KDR FLT3 FGFR1 FGF1

GO Terms for 8p11 Myeloproliferative Syndrome

Cellular components related to 8p11 Myeloproliferative Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.83 TRIM24 TPR RANBP2 PDGFRB NSMAF MYO18A
2 nuclear pore nuclear basket GO:0044615 9.26 TPR RANBP2
3 nuclear inclusion body GO:0042405 9.16 TPR RANBP2
4 receptor complex GO:0043235 9.02 PDGFRB KIT KDR FLT3 FGFR1

Biological processes related to 8p11 Myeloproliferative Syndrome according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 multicellular organism development GO:0007275 10.09 PDGFRB KIT KDR FLT3 FGFR1 FGF1
2 phosphorylation GO:0016310 10.02 PDGFRB KIT KDR FLT3 FGFR1 BCR
3 protein phosphorylation GO:0006468 10 TRIM24 PDGFRB KIT KDR FLT3 FGFR1
4 positive regulation of cell proliferation GO:0008284 9.95 PDGFRB KIT KDR FLT3 FGFR1 FGF1
5 MAPK cascade GO:0000165 9.91 PDGFRB KIT FLT3 FGFR1 FGF1
6 cell migration GO:0016477 9.89 PDGFRB MYO18A KDR FGFR1
7 positive regulation of cell migration GO:0030335 9.89 PDGFRB KIT KDR FGF1 CEP43
8 positive regulation of protein kinase B signaling GO:0051897 9.86 PDGFRB KIT FGFR1 FGF1
9 positive regulation of MAPK cascade GO:0043410 9.83 KIT KDR FLT3 FGFR1
10 hematopoietic progenitor cell differentiation GO:0002244 9.78 PDGFRB KIT KDR FLT3
11 wound healing GO:0042060 9.77 PDGFRB FGFR1OP2 FGF1
12 peptidyl-tyrosine phosphorylation GO:0018108 9.77 PDGFRB KIT KDR FLT3 FGFR1
13 hemopoiesis GO:0030097 9.75 RUNX1 KIT FLT3
14 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.72 PDGFRB KIT KDR FLT3 FGFR1
15 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.71 PDGFRB KIT FLT3
16 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.65 PDGFRB KIT KDR FLT3 FGFR1
17 embryonic hemopoiesis GO:0035162 9.61 KIT KDR
18 vascular endothelial growth factor signaling pathway GO:0038084 9.61 KDR FLT3
19 positive regulation of phospholipase C activity GO:0010863 9.61 PDGFRB KIT FGFR1
20 organ induction GO:0001759 9.58 FGFR1 FGF1
21 myeloid progenitor cell differentiation GO:0002318 9.57 KIT FLT3
22 positive regulation of kinase activity GO:0033674 9.55 PDGFRB KIT KDR FLT3 FGFR1
23 positive regulation of MAP kinase activity GO:0043406 9.35 PDGFRB KIT FLT3 FGFR1 FGF1
24 protein autophosphorylation GO:0046777 9.17 TRIM24 PDGFRB KIT KDR FLT3 FGFR1

Molecular functions related to 8p11 Myeloproliferative Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.33 ZMYM2 TRIM24 TPR RUNX1 RANBP2 PDGFRB
2 transferase activity GO:0016740 10.08 TRIM24 RANBP2 PDGFRB KIT KDR FLT3
3 ATP binding GO:0005524 9.92 RUNX1 PDGFRB MYO18A KIT KDR FLT3
4 kinase activity GO:0016301 9.85 PDGFRB KIT KDR FLT3 FGFR1 BCR
5 protein kinase activity GO:0004672 9.73 TRIM24 PDGFRB KIT KDR FLT3 FGFR1
6 vascular endothelial growth factor binding GO:0038085 9.46 PDGFRB KDR
7 growth factor binding GO:0019838 9.46 PDGFRB KIT KDR FLT3
8 vascular endothelial growth factor-activated receptor activity GO:0005021 9.43 KDR FLT3
9 protein tyrosine kinase activity GO:0004713 9.35 PDGFRB KIT KDR FLT3 FGFR1
10 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.02 PDGFRB KIT KDR FLT3 FGFR1

Sources for 8p11 Myeloproliferative Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....